Abstract
Immunization with a recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B induced strong specific T-helper cell responses in asymptomatic human immunodeficiency virus (HIV) carriers infected with subtypes B to G. This indicates that the HIV-specific T-helper immunity, which is the basis for development of antibodies and cytotoxic T lymphocytes, can be improved by both homologous and heterologous antigens. It also suggests that a particular immunogen can be effective against many different HIV strains.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / administration & dosage
-
AIDS Vaccines / immunology*
-
Cross Reactions
-
HIV Envelope Protein gp160 / administration & dosage
-
HIV Envelope Protein gp160 / genetics
-
HIV Envelope Protein gp160 / immunology
-
HIV Infections / immunology*
-
HIV Infections / virology
-
HIV-1 / classification
-
HIV-1 / immunology*
-
Humans
-
Lymphocyte Activation
-
T-Lymphocytes, Helper-Inducer / immunology*
-
Vaccination
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology
Substances
-
AIDS Vaccines
-
HIV Envelope Protein gp160
-
Vaccines, Synthetic
-
VaxSyn HIV-1 (gp160) vaccine